Novartis’ Cosentyx available on NHS in Scotland

pharmafile | January 19, 2021 | News story | Manufacturing and Production Novartis 

Novartis has announced that Cosentyx (secukinumab) 150mg is available in Scotland on the NHS, licensed for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) who have responded inadequately to non-steroidal anti-inflammatory drugs, following approval by the Scottish Medicines Consortium (SMC).

The SMC recommendation is based on data from the Phase III PREVENT study, which showed significantly more patients treated with secukinumab 150mg achieved a significant and clinically meaningful reduction in nr-axSpA disease activity versus placebo, as measured by at least 40% improvement in ASAS40 (Assessment in Ankylosing Spondylitis) at week 16.

Statistically significant improvements in secondary endpoints were also demonstrated, including pain, disease burden and health-related quality of life. The trial demonstrated a safety profile of secukinumab consistent with previous clinical trials, with no new or unexpected safety signals detected. The most frequent treatment-emergent adverse events up to week 20 were nasopharyngitis, diarrhoea, headache, and upper respiratory tract infection in both the secukinumab and placebo groups.

Dr Dale Webb, Chief Executive of the UK’s National Axial Spondyloarthritis Society commented: “We’re delighted the SMC has decided to make secukinumab available for people in Scotland living with non-radiographic axial spondyloarthritis.

“Nr-axSpA can cause chronic pain, fatigue, difficulty sleeping due to nocturnal pain and reduced work productivity, which can have a profound and long-lasting impact on patients’ quality of life. Having access to a new treatment option which may offer welcome relief from the often-debilitating symptoms of nr-axSpA, is a significant development.”                                                     

Dr David Crosbie, Consultant Rheumatologist at the Queen Elizabeth University Hospital, Glasgow, said: “The availability of secukinumab means that clinicians in Scotland now have a treatment option for nr-axSpA with a second mode of action.

“It can be incredibly frustrating and painful for a patient when they don’t respond to treatment. This means we have an additional opportunity to find a treatment that works for them, with the potential to make a real difference to the lives of our patients.”

Darcy Jimenez

Related Content

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …


AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the …

Novartis announce digital collaboration with HPE

Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate …

Latest content